Skip to main content

Zai Lab Ltd

corporate_fare Company Profile

Zai Lab Ltd

ZLAB·NASDAQ·Life Sciences·CIK 0001704292

We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We focus on discovering, developing, and commercializing products for medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease. Our experienced team has formed partnerships with leading global biopharmaceutical companies, resulting in a broad pipeline that includes multiple commercial products and multiple programs in late-stage clinical development. We also have an in-house research and development team with strong product discovery and translational research capabilities, and we are developing a pipeline of proprietary product candidates with global rights. Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients. To achieve this, our strategy involves three pillars: accelerating medicines to patients by investing in research and development, expanding and strengthening our global and regional pipelines through internal discovery and collaborations, and continuing our commercial excellence and execution by increasing access to existing commercial products and improving efficiency as we prepare for new product launches or new indications for existing products.

Zai Lab Ltd (NASDAQ:ZLAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for ZLAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-14, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for ZLAB spans 10-Q, 8-K, 144, DEF 14A.

Recent high-impact activity:

  • KarXT and VYVGART Hytrulo Win First-Time China NRDL Coverage for 2027
  • Zoci Hits 40% Confirmed Response Rate in Hard-to-Treat Neuroendocrine Carcinomas
  • Zai Lab 10-Q: Q3 Revenue Falls 7% to $108.2M, Net Loss Widens to $46.1M
  • Zai Lab Q3 Revenue Slips 7% as Inventory Write-Down Widens Net Loss to $46.1M
  • Zoci-Atezolizumab Doublet Hits 81.8% Response Rate in First-Line SCLC

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$460.16M
Net Income
-$175.54M
Diluted EPS
-$0.16
Op. Cash Flow
-$150.79M
Free Cash Flow
-$158.89M
Gross Profit
$269.64M
Operating Income
-$229.43M
Cash & Equivalents
$679.57M
Total Debt
$204.53M
Debt / Equity
0.29×
Net Margin
-38.1%
Shares Outstanding
1.11B sh
Source: 10-K · filed 2026-02-26 · accession 0001704292-26-000015

Short Interest & Short Volume

6.67 days to cover

FINRA reported short interest of 8,092,682 shares in ZLAB as of the October 30, 2026 settlement, a 8.5% decrease from the prior period — about 6.7 days to cover at its recent average daily volume. On November 20, 2026, 66.7% of ZLAB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,092,682 shares as of October 30, 2026
Change vs prior period▼ 8.5%
Days to cover6.67 at avg daily volume of 1,213,439
Daily short volume (FINRA facilities)66.7% of 621,617 shares on November 20, 2026
5-day average short volume59.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with Z →
$21.03
52-week range · as of 2026-11-05 $15.96 – $27.5
Market cap
$2.62B
Volume
1.4M (1.2× avg)
3-mo avg 1.2M
Live data · 2026-11-21 19:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZLAB - Latest Insights

ZLAB
Nov 13, 2026, 10:26 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $24.60
Real-time Price: $21.03 info
Change: -$3.57 (-15%) info
Market Cap: $2.624B info
ZLAB
Nov 05, 2026, 9:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $23.19
Real-time Price: $21.03 info
Change: -$2.16 (-9%) info
Market Cap: $2.624B info
ZLAB
Nov 05, 2026, 6:41 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $23.19
Real-time Price: $21.03 info
Change: -$2.16 (-9%) info
Market Cap: $2.624B info
ZLAB
Nov 05, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $23.19
Real-time Price: $21.03 info
Change: -$2.16 (-9%) info
Market Cap: $2.624B info
ZLAB
Oct 23, 2026, 6:33 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $22.87
Real-time Price: $21.03 info
Change: -$1.84 (-8%) info
Market Cap: $2.624B info
ZLAB
Oct 23, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.87
Real-time Price: $21.03 info
Change: -$1.84 (-8%) info
Market Cap: $2.624B info
ZLAB
Oct 23, 2026, 2:26 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $22.14
Real-time Price: $21.03 info
Change: -$1.11 (-5%) info
Market Cap: $2.624B info
ZLAB
Aug 06, 2026, 6:40 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.64
Real-time Price: $21.03 info
Change: +$2.39 (+13%) info
Market Cap: $2.624B info
ZLAB
Aug 06, 2026, 6:34 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.64
Real-time Price: $21.03 info
Change: +$2.39 (+13%) info
Market Cap: $2.624B info
ZLAB
Jun 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.88
Real-time Price: $21.03 info
Change: +$3.15 (+18%) info
Market Cap: $2.624B info
ZLAB
May 21, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.10
Real-time Price: $21.03 info
Change: +$1.93 (+10%) info
Market Cap: $2.624B info
ZLAB
May 18, 2026, 11:34 AM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $18.95
Real-time Price: $21.03 info
Change: +$2.08 (+11%) info
Market Cap: $2.624B info
ZLAB
May 15, 2026, 9:49 AM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $21.22
Real-time Price: $21.03 info
Change: -$0.185 (-0.87%) info
Market Cap: $2.624B info
ZLAB
May 07, 2026, 6:09 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.99
Real-time Price: $21.03 info
Change: +$0.040 (+0.19%) info
Market Cap: $2.624B info
ZLAB
Apr 28, 2026, 7:16 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $21.99
Real-time Price: $21.03 info
Change: -$0.960 (-4%) info
Market Cap: $2.624B info
ZLAB
Apr 17, 2026, 7:12 AM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $23.49
Real-time Price: $21.03 info
Change: -$2.46 (-10%) info
Market Cap: $2.624B info
ZLAB
Feb 26, 2026, 7:08 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $19.30
Real-time Price: $21.03 info
Change: +$1.73 (+9%) info
Market Cap: $2.624B info
ZLAB
Feb 26, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.20
Real-time Price: $21.03 info
Change: +$1.83 (+10%) info
Market Cap: $2.624B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets